Compare BH & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BH | SPRY |
|---|---|---|
| Founded | 1934 | 2015 |
| Country | United States | United States |
| Employees | 2359 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.1M | 823.2M |
| IPO Year | N/A | 2020 |
| Metric | BH | SPRY |
|---|---|---|
| Price | $303.21 | $8.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 58.0K | ★ 1.6M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | N/A | $81.64 |
| P/E Ratio | $597.67 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $230.12 | $6.66 |
| 52 Week High | $483.60 | $18.63 |
| Indicator | BH | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 53.70 |
| Support Level | $299.54 | $8.61 |
| Resistance Level | $321.70 | $9.46 |
| Average True Range (ATR) | 13.06 | 0.49 |
| MACD | 0.75 | 0.11 |
| Stochastic Oscillator | 74.42 | 53.39 |
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, and Oil and Gas Operations. Its restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The company also reports segment information for Maxim. The majority of revenue is derived from the Restaurant Operations Segment.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.